Medice
Privately held: no public share price · Germany
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Vadadustat(Vafseo) | Approved | HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule | Chronic Kidney Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Akebia Therapeutics · Source ↗
June 2026Topline resultVadadustatVOICE interim analysis met the predefined stopping criteria (non-inferiority and superiority on the primary composite endpoint)
Financial reports
No financial reports recorded.